SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+6.89%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$491M
AUM Growth
+$491M
(+25%)
Cap. Flow
+$65.6M
Cap. Flow
% of AUM
13.37%
Top 10 Holdings %
Top 10 Hldgs %
36.88%
Holding
146
New
36
Increased
29
Reduced
18
Closed
21
Top Buys
| 1 |
GSK
GSK
|
$19.4M |
| 2 |
Gilead Sciences
GILD
|
$16.3M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.2M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$8.71M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$7.69M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$24.1M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$7.09M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$5.52M |
| 4 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$5.08M |
| 5 |
Novartis
NVS
|
$4.39M |
Sector Composition
| 1 | Healthcare | 79.26% |
| 2 | Technology | 7.56% |
| 3 | Industrials | 3.16% |
| 4 | Communication Services | 2.73% |
| 5 | Financials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $32.5M | 5.52% | 250,000 | – | – |
|
2
Biogen
BIIB
$19.4B
| $24.4M | 4.15% | 90,000 +15,000 | +20% | +$4.07M |
|
3
Merck
MRK
$210B
| $20.5M | 3.48% | 320,000 +25,000 | +8% | +$1.6M |
|
|
4
GSK
GSK
$79.9B
| $19.4M | 3.3% | +450,000 | New | +$19.4M |
|
|
5
Gilead Sciences
GILD
$140B
| $16.3M | 2.77% | +230,000 | New | +$16.3M |
|
|
6
Novartis
NVS
$245B
| $16M | 2.71% | 200,000 -55,000 | -22% | -$4.39M |
|
7
Bristol-Myers Squibb
BMY
$96B
| $13.8M | 2.35% | 248,000 +98,000 | +65% | +$5.46M |
|
8
Pfizer
PFE
$141B
| $13.1M | 2.23% | 390,000 | – | – |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $12.9M | 2.19% | 383,047 -100,000 | -21% | -$3.37M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $12.2M | 2.07% | +100,000 | New | +$12.2M |
|
|
SHPG
11
DELISTED
Shire pic
SHPG
| $11.3M | 1.92% | 68,500 -146,039 | -68% | -$24.1M |
|
12
Ituran Location and Control
ITRN
$671M
| $9.53M | 1.62% | 304,421 +23,065 | +8% | +$722K |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $8.71M | 1.48% | +93,000 | New | +$8.71M |
|
|
TSRO
14
DELISTED
TESARO, Inc.
TSRO
| $7.69M | 1.31% | +55,000 | New | +$7.69M |
|
|
ORBK
15
DELISTED
Orbotech Ltd
ORBK
| $6.97M | 1.18% | 213,740 +56,644 | +36% | +$1.85M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.81M | 1.16% | +75,000 | New | +$6.81M |
|
17
Nice
NICE
$8.73B
| $6.7M | 1.14% | 85,052 +21,532 | +34% | +$1.69M |
|
|
ARAV
18
DELISTED
Aravive, Inc. Common Stock
ARAV
| $6.59M | 1.12% | 377,524 +77,524 | +26% | +$1.35M |
|
|
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
| $5.86M | 1% | 700,000 | – | – |
|
|
PVLA
20
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $5.57M | 0.95% | 1,100,000 +100,000 | +10% | +$506K |
|
21
FibroGen
FGEN
$47.8M
| $5.35M | 0.91% | 165,700 | – | – |
|
|
CLLS
22
Cellectis
CLLS
$258M
| $5.26M | 0.89% | 203,764 +44,100 | +28% | +$1.14M |
|
23
Visa
V
$683B
| $4.97M | 0.84% | 52,951 | – | – |
|
|
AVEO
24
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $4.88M | 0.83% | 2,200,000 -700,000 | -24% | -$1.55M |
|
25
Meta Platforms (Facebook)
META
$1.86T
| $4.86M | 0.83% | 32,167 +14,075 | +78% | +$2.13M |
|